Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Pharmaceutical composition for lowering blood lipid

The technology of a composition and a lipid-lowering drug, applied in the field of medicine, can solve the problems of unsatisfactory treatment effect and the like, and achieve the effect of significant curative effect and lowering cholesterol.

Inactive Publication Date: 2012-02-15
FUKANGREN BIO PHARMA
View PDF0 Cites 6 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

In recent years, a variety of blood lipid-lowering drugs have been launched one after another, which has increased the safety of patients with hyperlipidemia, but the therapeutic effect is still not ideal, so seeking a good and stable blood lipid-lowering drug is still the direction of new drug development in the future

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Pharmaceutical composition for lowering blood lipid
  • Pharmaceutical composition for lowering blood lipid
  • Pharmaceutical composition for lowering blood lipid

Examples

Experimental program
Comparison scheme
Effect test

specific Embodiment 1

[0014] Specific Example 1 Ezetimibe / niacin composition

[0015] In this example, niacin and corresponding pharmaceutical excipients were used to prepare tablet cores, and the corresponding OPadry II clear suspension was sprayed on the niacin tablet cores to prepare a separation layer between niacin and ezetimibe, and ezetimibe was mixed with corresponding OPadry II White suspension is sprayed on the niacin tablet core with a barrier layer and film-coated.

[0016] Preparation of Nicotinic Acid Tablets

[0017] Table 1

[0018]

[0019]

[0020] Process: Mix niacin, 57.5 grams of hypromellose, and PVP K90 evenly, make soft material with purified water, granulate, dry, granulate, add the remaining hypromellose and stearic acid, mix evenly, press piece.

[0021] Preparation of isolation layer

[0022] Table 2

[0023]

[0024] Process: Disperse OPadry II clear coating powder in water and stir evenly; adjust the coating parameters, spray the coating powder suspension...

specific Embodiment 2

[0032] Specific Example 2 Ezetimibe / Etofibrate Composition

[0033] In this example, etofibrate and corresponding pharmaceutical excipients were made into pellets, sieved, and coated with an isolation coat to obtain etofibrate pellets; ezetimibe was mixed with corresponding pharmaceutical excipients to be evenly granulated, dried, Sieve to obtain ezetimibe granules; Etobet pellets, ezetimibe granules and corresponding pharmaceutical excipients are uniformly mixed, pressed into tablets, and coated.

[0034] Preparation of Etofibrate pellets

[0035]

[0036] Process: Mix powdered sugar and starch, add part of Etofibrate and mix evenly, dissolve shellac in ethanol to make it a 14.5% solution, granulate this solution to make the particle size between 125-800 μm, and obtain Etofibrate nuclear.

[0037] 2. Laminate Etobeta on the mother core, use 30kg of ethanol as a binder, make the particle size of the pellets 630-1250 μm, and finally coat with 40% shellac, and continuously ...

Embodiment 3

[0044] Embodiment 3: lipid-lowering effect experiment

[0045] Male Wistar rats (grade 2), weighing 160-170 g. Give high-fat diet 25g (high-fat diet formula: basic feed: cholesterol: lard: cholate: methylthiouracil = 8418: 4: 10: 1: 012) every day in a quantitative manner, and continue for 26 days to establish hyperlipidemia. mouse model.

[0046] In addition to a blank control group (group 0) that was not given high-fat feed, the experimental animals that successfully established the model were randomly divided into 9 groups, namely group A (model control); group B (ezetimibe) : dosage 10mg / time; group C (compound ezetimibe niacin); group D (compound acipimus ezetimibe); group E (compound nitrobetel ezetimibe); group F (compound ezetimibe fenofibrate ezetimibe); group G (compound bezafibrate ezetimibe); group H (compound etobate ezetimibe); group I (compound ciprofibrate ezetimibe) . All the drugs were suspended in 0.5% sodium carboxymethylcellulose and administered by in...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention relates to an oral pharmaceutical composition for lowering blood lipid, and particularly relates to a pharmaceutical composition with any one substance of ezetimibe and nicotinic acid lipid-lowering drugs or Beite lipid-lowering drugs as an active ingredient as well as a preparation and application thereof. The pharmaceutical composition is an oral preparation prepared from ezetimibe and nicotinic acid lipid-lowering drugs or Beite lipid-lowering drugs used as the active ingredient and corresponding pharmaceutical auxiliary materials according to the technique and method provided by the invention; and the pharmaceutical composition can be prepared into granules, common tablets, chewing tablets, dispersing tablets, oral disintegrating tablets, oral lozenge, capsules, soft capsules, dropping pills, sustained-release tablets, sustained-release capsules and the like. The pharmaceutical composition has rapid and durable action, is convenient to take, and can be used for treating various types of hyperlipemia.

Description

technical field [0001] The invention relates to a pharmaceutical composition for lowering blood fat, which belongs to the technical field of medicine. Background technique [0002] Hyperlipidemia refers to high cholesterol (TC) and / or triglyceride (TG) or low high-density lipoprotein cholesterol (HDL-C) in the blood. The damage to the body of the disease is hidden, gradual, progressive and systemic. sexual. Its direct damage is to accelerate systemic atherosclerosis, because vital organs of the whole body rely on arterial blood supply and oxygen supply. Once the arteries are blocked by atherosclerotic plaques, serious consequences will result. Renal failure caused by arteriosclerosis is closely related to hyperlipidemia. A large number of research data show that hyperlipidemia is an independent and important risk factor for stroke, coronary heart disease, myocardial infarction, and sudden cardiac death. In recent years, a variety of blood lipid-lowering drugs have been la...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
IPC IPC(8): A61K31/4965A61K31/455A61K31/397A61K31/216A61K31/192A61P3/06
Inventor 不公告发明人
Owner FUKANGREN BIO PHARMA
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com